Nektar Therapeutics
NASDAQ: NKTR
$1.37
-$0.02 (-1.4%)
Closing Price on November 7, 2024
NKTR Articles
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Altice USA, CVS Health, Exxon, Lowe's, T-Mobile, Sprint and Under Armour.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include BlackBerry, BP, Camping World, Deere, GrubHub, KLA-Tencor, Teva Pharmaceutical and Zions Bancorp.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday include AK Steel, Amazon.com, AngloGold Ashanti, Bank of America, General Electric, Walt Disney and Xilinx.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday include Carnival, Facebook, Freeport-McMoRan, Motorola Solutions and Procter & Gamble.
Published:
Last Updated:
Esperion Therapeutics and a few other biopharma stocks made massive runs on Monday morning.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday, January 6, include Cognizant Technology Solutions, Etsy, GoPro, Illumina, Shake Shack and Travelers Companies.
Published:
Last Updated:
With the busiest earnings week behind us, it appears some of the restriction windows at major U.S. corporations are starting to open up a little.
Published:
Last Updated:
Nektar Therapeutics plans to price 13 million shares at $13.50 for a secondary offering valued up to almost $202 million.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
Published:
Last Updated:
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
Published:
The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight.
Published:
On the close Friday, the NYSE Arca Biotechnology Index is set for a rebalance. These four stocks that could see the highest amount of share count buying.
Published:
The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
Published:
The Quantitative Strategies team at Jefferies closely monitors the index changes. 24/7 Wall St. screened the Jefferies list of stocks that will see major position adds for the rebalance. Some of them...
Published: